Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report
Year: 2026
Type: article
Abstract: Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD) is a heterogeneous condition characterized by chronic eosinophilic airway inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma whose symptoms are aggravated after ingestion of aspirin and other NSAIDs. As a unique treatment, aspirin treatment after desensitization (ATAD) has been in use for several years after showing the inhibitory effect on CRS symptoms and nasal polyp growth as well as severe asthma. However, in recent years, biologics have also shown to cause a decrease in polyp size as well as associated outcomes such as quality of life. In this manuscript, considerations on choosing the best treatment of NSAID-ERD are laid out based on current literature.
Source: Allergy
DOI: 10.1111/all.70243
Institutions: Ankara University, Medical University of Lodz, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Hospital Regional Universitario de Málaga, Brigham and Women's Hospital, Harvard University, University of Florence, University of Helsinki, University of Eastern Finland, Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Zentrum für Rhinologie und Allergologie, Istanbul University, Inserm, Sorbonne Université, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Hôpital Tenon, University of Copenhagen, Copenhagen University Hospital, Gentofte Hospital, University of Toronto, Hospital for Sick Children, Universitätsklinikum St. Pölten, Karl Landsteiner University of Health Sciences, Scripps Clinic Medical Group
Language: English
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: G7217935449
OpenAlex ID: W7127933571